Leland Stanford Junior University

Targesome, Inc.

Alliant Techsystems Inc.

Orbital Atk, Inc.

Epicentrx, Inc.

The Scripps Research Institute

Other

Radiorx, Inc.

Mark David Bednarski

King Chuen Li

Louis F Cannizzo

Stephen P Velarde

Kirstin F Warner

Robert B Wardle

Susan Knox

Shoucheng Ning

Jeremy Kenji Kuniyoshi

Henry Y Li

Dorothy Anna Sipkins

Francois Daniel Tropper

Richard Wood Storrs

Curtis Kang Song

John Hood

David A Cheresh

Samira Guccione

Curtis Kang Hoon Song

Lynn M Oehler, Legal Representative

Francois D Trooper

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof

The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

O-nitro compounds and pharmaceutical compositions including same

Pharmaceutical compositions of O-nitro compounds

The in vivo delivery of nucleic acids is targeted by delivery of the nucleic acid in a complex with cross-linked nanoparticles; where the nanoparticles comprise cross-linked neutral amphipathic molecules, cationic amphipathic molecules and targeting amphipathic molecules. Optionally the cationic and targeting amphipathic molecules are also cross-linked. A targeting moiety present on the targeting amphipathic molecule provides for selective delivery of the complex to a predetermined target site, e.g. blood vessels, endothelial cells, tumor cells, liver cells, and the like.

Targeted cross-linked nanoparticles and their use in vivo gene delivery

&#x3b1;&#x3b2;Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic &#x3b1;&#x3b2;integrin antagonist.

Delivery system for nucleic acids

Use of targeted cross-linked nanoparticles for in vivo gene delivery

Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and/or linked to or encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.

Targeted polymerized liposome diagnostic and treatment agents

Use of polymerized lipid diagnostic agents

Targeted tissue in vivo is altered using focused energy to specifically control endothelial permeability and interstitial integrity. Image guidance may be used in combination with physical energy deposition to facilitate the targeted delivery of materials. The method of the invention serves as a platform for delivering pharmaceutical agents, nucleic acids, proteins, liposomes, etc. to cells.

Enhancement of bioavailability by use of focused energy delivery to a

Growing community of inventors

Los Altos, CA, United States of America

Mark David Bednarski